Stone House Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

Stone House Investment Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-81	Closed	-$1.63K	–	1392
2026 Q1	$1.63K	Buy	81 +67	+479%	+$1.08K	﹤0.01%	626
2025 Q4	$226	Buy	+14	New	+$185	﹤0.01%	792

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Stone House Investment Management's KALV Position: Q2 2026 in Review

Stone House Investment Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 81 shares — an estimated $1.63K sold.

Stone House Investment Management first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $1.63K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Stone House Investment Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Stone House Investment Management sold 81 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.63K.
Stone House Investment Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Stone House Investment Management's KalVista Pharmaceuticals position peaked at $1.63K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.